<div>Notes: *: <i>p</i> &lt;.05; chi² test, t-test for independent
groups IQR - interquartile range, Md - median</div><div>Figure 1:</div><div>Map of Bavaria with location of centers contributing to the survey (red
dots) and COVID-19 prevalence until July 2020 (color coded by county).
Number for overall, negatively and positively tested children are given
in the circle chart</div><div>Figure 2:</div><div>Comparison between the N protein directed Elecsys Anti-SARS-CoV-2 assay
(total Ig) and the S protein directed in-house SARS-CoV-2 assay
detecting IgG (IgG) in the total study population (N=2832). Strong
dotted lines represent the assay cutoff values, ±10% borderline
intervals (gray areas). Signal-to-cutoff (S/Co) ratios are given for
both assays.</div><div>Figure 3:</div><div>Study flowchart (upper panel) and findings from the follow-up of
SARS-CoV-2 seropositive children for PMIS symptoms in the CoKiBa study
(lower panel)</div><div>Legend: * only those 52 individuals who actively contacted their
pediatrician could be included into the follow up. Due to the anonymous
design of the study no reminder was possible. ** Individuals could
report more than one symptom. AB is antibody, LDH is lactate
dehydrogenase</div><div>Figure 4:</div><div>Neutralizing and S-protein specific binding antibody titer analysis of
children from follow up with N-specific signal S/Co&gt;100</div><div>Legend: <b>A.</b> Correlation of N-specific antibody signal (Elecsys,
S/Co) with neutralizing antibody titers. <b>B.</b> Correlation of
S-protein ELISA binding antibody titers (S/Co) with neutralizing
antibody titers. <b>C.</b> Dotplot representation of the neutralizing
antibody titers of all children examined in the follow up study,
visualizing symptomatic children by dot colour and shape. <b>D</b> .
Pie chart distribution of symptomatic children grouped according to
neutralizing antibody titer. <b>E.</b> Comparison of the
neutralization capacity of symptomatic and asymptomatic children.</div>